BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao N, Di B, Xu LL. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies. Cytokine Growth Factor Rev 2021:S1359-6101(21)00054-X. [PMID: 34183243 DOI: 10.1016/j.cytogfr.2021.06.002] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 40.0] [Reference Citation Analysis]
Number Citing Articles
1 Aktar S, Amin S. SARS-CoV-2 mediated dysregulation in cell signaling events drives the severity of COVID-19. Virus Res 2022;323:198962. [PMID: 36209917 DOI: 10.1016/j.virusres.2022.198962] [Reference Citation Analysis]
2 Batiha GE, Al-kuraishy HM, Al-gareeb AI, Alruwaili M, Alruwaili R, Albogami SM, Alorabi M, Saad HM, Simal-gandara J. Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal. Inflammopharmacol 2022. [DOI: 10.1007/s10787-022-01087-8] [Reference Citation Analysis]
3 Forsyth CB, Voigt RM, Swanson GR, Bishehsari F, Shaikh M, Zhang L, Engen P, Keshavarzian A. Alcohol use disorder as a potential risk factor for COVID ‐19 severity: A narrative review. Alcohol Clin & Exp Res 2022. [DOI: 10.1111/acer.14936] [Reference Citation Analysis]
4 Shin SW, Cho IH. Panax ginseng as a potential therapeutic for neurological disorders associated with COVID-19; Toward targeting inflammasome. J Ginseng Res 2022. [PMID: 36213093 DOI: 10.1016/j.jgr.2022.09.004] [Reference Citation Analysis]
5 Gomaa AA, Abdel-Wadood YA, Gomaa MA. Glycyrrhizin and boswellic acids, the golden nutraceuticals: multitargeting for treatment of mild-moderate COVID-19 and prevention of post-COVID cognitive impairment. Inflammopharmacology 2022. [PMID: 36136251 DOI: 10.1007/s10787-022-01062-3] [Reference Citation Analysis]
6 Arjsri P, Srisawad K, Mapoung S, Semmarath W, Thippraphan P, Umsumarng S, Yodkeeree S, Dejkriengkraikul P. Hesperetin from Root Extract of Clerodendrum petasites S. Moore Inhibits SARS-CoV-2 Spike Protein S1 Subunit-Induced NLRP3 Inflammasome in A549 Lung Cells via Modulation of the Akt/MAPK/AP-1 Pathway. IJMS 2022;23:10346. [DOI: 10.3390/ijms231810346] [Reference Citation Analysis]
7 Jiang Y, Zhao T, Zhou X, Xiang Y, Gutierrez‐castrellon P, Ma X. Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions. MedComm 2022;3. [DOI: 10.1002/mco2.154] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Chen Y, zhang W, Yu Y, Chen X, Jiang G, Ou G, Liu Q, Jiang L, Chen J. Identification of transcriptomics biomarker for the early prediction of critically ill COVID-19 patients.. [DOI: 10.21203/rs.3.rs-1838856/v1] [Reference Citation Analysis]
9 Maes M, Al-Rubaye HT, Almulla AF, Al-Hadrawi DS, Stoyanova K, Kubera M, Al-Hakeim HK. Lowered Quality of Life in Long COVID Is Predicted by Affective Symptoms, Chronic Fatigue Syndrome, Inflammation and Neuroimmunotoxic Pathways. Int J Environ Res Public Health 2022;19:10362. [PMID: 36011997 DOI: 10.3390/ijerph191610362] [Reference Citation Analysis]
10 Sergi CM. NLRP-3 Inflammasome: A Key Target, but Mostly Overlooked following SARS-CoV-2 Infection. Vaccines (Basel) 2022;10:1307. [PMID: 36016195 DOI: 10.3390/vaccines10081307] [Reference Citation Analysis]
11 Xiong L, Cao J, Yang X, Chen S, Wu M, Wang C, Xu H, Chen Y, Zhang R, Hu X, Chen T, Tang J, Deng Q, Li D, Yang Z, Xiao G, Zhang X. Exploring the mechanism of action of Xuanfei Baidu granule (XFBD) in the treatment of COVID-19 based on molecular docking and molecular dynamics. Front Cell Infect Microbiol 2022;12:965273. [DOI: 10.3389/fcimb.2022.965273] [Reference Citation Analysis]
12 Niu X, Song H, Xiao X, Yang Y, Huang Q, Yu J, Yu J, Liu Y, Han T, Zhang D, Li W. Tectoridin ameliorates proliferation and inflammation in TNF-α-induced HFLS-RA cells via suppressing the TLR4/NLRP3/NF-κB signaling pathway. Tissue and Cell 2022;77:101826. [DOI: 10.1016/j.tice.2022.101826] [Reference Citation Analysis]
13 Yong Y, Zhang L, Hu Y, Wu J, Yan L, Pan Y, Tang Y, Yu L, Law BY, Yu C, Zhou J, Li M, Qin D, Zhou X, Wu A. Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19. Clinical Immunology 2022. [DOI: 10.1016/j.clim.2022.109093] [Reference Citation Analysis]
14 Maes M, Al-rubaye HT, Almulla AF, Al-hadrawi DS, Stoyanova K, Kubera M, Al-hakeim HK. Lowered quality of life in Long COVID is strongly predicted by affective symptoms and chronic fatigue syndrome which are associated with inflammatory processes during the acute infectious phase and consequent neuroimmunotoxic pathways.. [DOI: 10.1101/2022.07.25.22277980] [Reference Citation Analysis]
15 Al-hakeim HK, Al-rubaye HT, Almulla AF, Al-hadrawi DS, Maes M. Chronic fatigue, depression and anxiety symptoms in Long COVID are strongly predicted by neuroimmune and neuro-oxidative pathways which are caused by the inflammation during acute infection.. [DOI: 10.1101/2022.06.29.22277056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Farooq M, Khan AW, Ahmad B, Kim MS, Choi S. Therapeutic Targeting of Innate Immune Receptors Against SARS-CoV-2 Infection. Front Pharmacol 2022;13:915565. [DOI: 10.3389/fphar.2022.915565] [Reference Citation Analysis]
17 Matarazzo L, Hernandez Santana YE, Walsh PT, Fallon PG. The IL-1 cytokine family as custodians of barrier immunity. Cytokine 2022;154:155890. [DOI: 10.1016/j.cyto.2022.155890] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Chemarin M, Dufies O, Mazet A, Mellan E, Coudereau R, Py BF, Boyer L, Venet F. [Role of inflammasome NLRP3 in the pathophysiology of viral infections: A focus on SARS-CoV-2 infection]. Med Sci (Paris) 2022;38:545-52. [PMID: 35766852 DOI: 10.1051/medsci/2022080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Tavalaee M, Rahmani M, Drevet JR, Nasr-Esfahani MH. The NLRP3 inflammasome: molecular activation and regulation in spermatogenesis and male infertility; a systematic review. Basic Clin Androl 2022;32:8. [PMID: 35637440 DOI: 10.1186/s12610-022-00157-9] [Reference Citation Analysis]
20 Lin W, Li L, Hsiao Y, Wong W, Chiu H, Hsu H, Peng Y, Ho C, Chernikov OV, Cheng S, Yang S, Hua K. Repositioning of the Angiotensin II Receptor Antagonist Candesartan as an Anti-Inflammatory Agent With NLRP3 Inflammasome Inhibitory Activity. Front Immunol 2022;13:870627. [DOI: 10.3389/fimmu.2022.870627] [Reference Citation Analysis]
21 Caufriez A, Tabernilla A, Van Campenhout R, Cooreman A, Leroy K, Sanz Serrano J, Kadam P, Dos Santos Rodrigues B, Lamouroux A, Ballet S, Vinken M. Effects of Drugs Formerly Suggested for COVID-19 Repurposing on Pannexin1 Channels. Int J Mol Sci 2022;23:5664. [PMID: 35628472 DOI: 10.3390/ijms23105664] [Reference Citation Analysis]
22 Ercegovac M, Asanin M, Savic-radojevic A, Ranin J, Matic M, Djukic T, Coric V, Jerotic D, Todorovic N, Milosevic I, Stevanovic G, Simic T, Bukumiric Z, Pljesa-ercegovac M. Antioxidant Genetic Profile Modifies Probability of Developing Neurological Sequelae in Long-COVID. Antioxidants 2022;11:954. [DOI: 10.3390/antiox11050954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Niu X, Song H, Xiao X, Yu J, Yu J, Yang Y, Huang Q, Zang L, Han T, Zhang D, Li W. Tectoridin alleviates lipopolysaccharide -induced inflammaion via inhibiting TLR4-NF-κB/NLRP3 signaling in vivo and in vitro. Immunopharmacol Immunotoxicol 2022;:1-18. [PMID: 35506641 DOI: 10.1080/08923973.2022.2073890] [Reference Citation Analysis]
24 Bakhshi S, Shamsi S. MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes. International Immunopharmacology 2022;106:108595. [DOI: 10.1016/j.intimp.2022.108595] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
25 Yadav D, Agarwal S, Pancham P, Jindal D, Agarwal V, Dubey PK, Jha SK, Mani S, Rachana, Dey A, Jha NK, Kesari KK, Singh M. Probing the Immune System Dynamics of the COVID-19 Disease for Vaccine Designing and Drug Repurposing Using Bioinformatics Tools. Immuno 2022;2:344-71. [DOI: 10.3390/immuno2020022] [Reference Citation Analysis]
26 Fu Y, Ho W, Kang N, Tsai M, Wu J, Huang L, Weng C. Pharmaceutical Prospects of Curcuminoids for the Remedy of COVID-19: Truth or Myth. Front Pharmacol 2022;13:863082. [DOI: 10.3389/fphar.2022.863082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Maggi E, Azzarone BG, Canonica GW, Moretta L. What we know and still ignore on COVID-19 immune pathogenesis and a proposal based on the experience of allergic disorders. Allergy 2022;77:1114-28. [PMID: 34582050 DOI: 10.1111/all.15112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Djukic T, Stevanovic G, Coric V, Bukumiric Z, Pljesa-ercegovac M, Matic M, Jerotic D, Todorovic N, Asanin M, Ercegovac M, Ranin J, Milosevic I, Savic-radojevic A, Simic T. GSTO1, GSTO2 and ACE2 Polymorphisms Modify Susceptibility to Developing COVID-19. JPM 2022;12:458. [DOI: 10.3390/jpm12030458] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
29 Saeedi-boroujeni A, Nashibi R, Ghadiri AA, Nakajima M, Salmanzadeh S, Mahmoudian-sani M, Hanafi MG, Sharhani A, Khodadadi A. Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial. Archives of Medical Research 2022. [DOI: 10.1016/j.arcmed.2022.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Head RJ, Lumbers ER, Jarrott B, Tretter F, Smith G, Pringle KG, Islam S, Martin JH. Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID-19 and response to treatment. Pharmacol Res Perspect 2022;10:e00922. [PMID: 35106955 DOI: 10.1002/prp2.922] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
31 Jung E, Lee G. Korean Red Ginseng, a regulator of NLRP3 inflammasome, in the COVID-19 pandemic. Journal of Ginseng Research 2022. [DOI: 10.1016/j.jgr.2022.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Darestani MN, Akbari A, Yaghobee S, Taheri M, Akbari S, Guven Y. COVID-19 Pandemic and Periodontal Practice: The Immunological, Clinical, and Economic Points of View. BioMed Research International 2022;2022:1-10. [DOI: 10.1155/2022/3918980] [Reference Citation Analysis]
33 Shohan M, Nashibi R, Mahmoudian-Sani MR, Abolnezhadian F, Ghafourian M, Alavi SM, Sharhani A, Khodadadi A. The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial. Eur J Pharmacol 2022;914:174615. [PMID: 34863994 DOI: 10.1016/j.ejphar.2021.174615] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 20.0] [Reference Citation Analysis]
34 Liao D. Apoptosis, necroptosis, and pyroptosis in health and disease. Mechanisms of Cell Death and Opportunities for Therapeutic Development 2022. [DOI: 10.1016/b978-0-12-814208-0.00008-7] [Reference Citation Analysis]
35 Đukić T, Stevanović G, Ćorić V, Bukumirić Z, Plješa-ercegovac M, Matić M, Jerotić Đ, Ašanin M, Ercegovac M, Ranin J, Milošević I, Simić T, Savić-radojevic A. The association of glutathione transferase omega polymorphisms with laboratory inflammatory parameters in COVID-19. Medicinska istraživanja 2022;55:59-66. [DOI: 10.5937/medi55-38002] [Reference Citation Analysis]
36 Aksoyalp ZŞ, Nemutlu-Samur D. Sex-related susceptibility in coronavirus disease 2019 (COVID-19): Proposed mechanisms. Eur J Pharmacol 2021;912:174548. [PMID: 34606834 DOI: 10.1016/j.ejphar.2021.174548] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
37 Amin S, Aktar S, Rahman MM, Hassan Chowdhury MM. NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity. Microbes Infect 2021;:104913. [PMID: 34838941 DOI: 10.1016/j.micinf.2021.104913] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
38 Farahani M, Niknam Z, Mohammadi Amirabad L, Amiri-Dashatan N, Koushki M, Nemati M, Danesh Pouya F, Rezaei-Tavirani M, Rasmi Y, Tayebi L. Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets. Biomed Pharmacother 2022;145:112420. [PMID: 34801852 DOI: 10.1016/j.biopha.2021.112420] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 22.0] [Reference Citation Analysis]
39 Rodal Canales FJ, Pérez-Campos Mayoral L, Hernández-Huerta MT, Sánchez Navarro LM, Matias-Cervantes CA, Martínez Cruz M, Cruz Parada E, Zenteno E, Ramos-Martínez EG, Pérez-Campos Mayoral E, Romero Díaz C, Pérez-Campos E. Interaction of Spike protein and lipid membrane of SARS-CoV-2 with Ursodeoxycholic acid, an in-silico analysis. Sci Rep 2021;11:22288. [PMID: 34782703 DOI: 10.1038/s41598-021-01705-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Thapa K, Verma N, Singh TG, Kaur Grewal A, Kanojia N, Rani L. COVID-19-Associated acute respiratory distress syndrome (CARDS): Mechanistic insights on therapeutic intervention and emerging trends. Int Immunopharmacol 2021;101:108328. [PMID: 34768236 DOI: 10.1016/j.intimp.2021.108328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
41 Rahman MH, Rana HK, Peng S, Kibria MG, Islam MZ, Mahmud SMH, Moni MA. Bioinformatics and system biology approaches to identify pathophysiological impact of COVID-19 to the progression and severity of neurological diseases. Comput Biol Med 2021;138:104859. [PMID: 34601390 DOI: 10.1016/j.compbiomed.2021.104859] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
42 Zandi M. ORF8a as a viroporin in SARS-CoV-2 infection? Cytokine Growth Factor Rev 2021:S1359-6101(21)00056-3. [PMID: 34362671 DOI: 10.1016/j.cytogfr.2021.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]